FDA Approves Esperion’s Nexlizet for Lowering LDL Cholesterol "Bad" LDL Cholesterol, Approvals, Atherosclerotic Cardiovascular Disease (ASCVD), Cholesterol Lowering, FDA, FDA/Regulatory, Fixed-Dose Combinations (FDCs), Non-statins, Statins The U.S. Food and Drug Administration approved Ann Arbor, Michigan-based Esperion’s Nexlizet (bempedoic acid and ezetimibe) for lowering LDL cholesterol. Read more February 27, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/02/Esperion-Nexlizet-Approval-BioSpace-2-27-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-02-27 12:34:322020-02-27 14:14:27FDA Approves Esperion's Nexlizet for Lowering LDL Cholesterol